Is it ethical to prescribe generic immunosuppressive drugs to renal transplant patients?

Canadian Journal of Kidney Health and Disease

Volumn 1, Issue 1, 2014, Pages

  Allard, Julie ^a   Fortin, Marie Chantal ^a,b  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Ethics; Generic drugs; Immunosuppressive drugs (ISDs); Transplantation

Indexed keywords

CYCLOSPORIN; GENERIC DRUG; IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN; TACROLIMUS;

AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; DOCTOR PATIENT RELATION; DRUG CONCENTRATION; DRUG COST; HEALTH CARE INDUSTRY; HEALTH CARE ORGANIZATION; HEALTH CARE QUALITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; JUSTICE; KIDNEY TRANSPLANTATION; MEDICAL ETHICS; PHYSICIAN ATTITUDE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK FACTOR;

EID: 84991037844     PISSN: None     EISSN: 20543581     Source Type: Journal    
DOI: 10.1186/s40697-014-0023-8     Document Type: Article

References (41)

1. Harrison JJ, SchiffJR, Coursol CJ, Daley CJ, Dipchand AI, Heywood NM, Keough-Ryan TM, Keown PA, Levy GA, Lien DC, Wichart JR, Cantarovich M: Generic immunosuppression in solid organ transplantation: a Canadian perspective. Transplantation 2012, 93:657-665.
2. Canadian Institute of Health Information: Drivers of Prescription Drugs Spending in Canada. Ottawa, Ontario: CIHI; 2012.
3. Institut national d'excellence en santé et en services sociaux: Avis au Ministre. Québec: INESS; 2014. Available from: https://www.inesss.qc.ca/fileadmin/doc/INESSS/Inscription_medicaments/Avis_au_ministre/Juin_ 2014/_AvisMinistre_WEB_innovateurs_2014_06.pdf (in French only).
4. Health Canada Guidance Document: Comparative bioavailability standards: formulations used for systemic effects. [cited 2014 April 23rd]. Ottawa: Health Canada; 2012. Available from: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/applic-demande/guide-ld/bio/gd_standards_ld_normes-eng.php#a2.1.1.6.
5. Taber DJ, Baillie GM, Ashcraft EE, Rogers J, Lin A, Afzal F, Baliga P, Rajagopalan PR, Chavin KD: Does bioequivalence between modified cyclosporine formulations translate into equal outcomes? Transplantation 2005, 80:1633-1635.
6. Lionberger R, Jiang W, Huang SM, Geba G: Confidence in generic drug substitution. Clin Pharmacol Ther 2013, 94:438-440.
7. Borra LC, Roodnat JI, Kal JA, Mathot RA, Weimar W, van Gelder T: High within-patient variability in the clearance of tacrolimus is a risk factor for poor long-term outcome after kidney transplantation. Nephrol Dial Transplant 2010, 8:2757-2763.
8. Alloway RR, Sadaka B, Trofe-Clark J, Wiland A, Bloom RD: A randomized pharmacokinetic study of generic tacrolimus versus reference tacrolimus in kidney transplant recipients. Am J Transplant 2012, 12:2825-2831.
9. Bloom RD, Trofe-Clark J, Wiland A, Alloway RR: A randomized, crossover pharmacokinetic study comparing generic tacrolimus vs. the reference formulation in subpopulations of kidney transplant patients. Clin Transplant 2013, 6:E685-E693.
10. Khatami SM, Taheri S, Azmandian J, Sagheb MM, Nazemian F, Razeghi E, Shahidi S, Sadri F, Shamshiri AR, Sayyah M: One-year multicenter double-blind randomized clinical trial on the efficacy and safety of generic cyclosporine (iminoral) in De novo kidney transplant recipients. Exp Clin Transplant 2013, published ahead of print. doi:10.6002/ect.2013.0139.
11. Danguilan RA, Lamban AB, Luna CA, Bacinillo M, Momongan MI: Pilot study on the efficacy and safety of generic mycophenolate mofetil (mycept) compared with cellcept among incident low-risk primary kidney transplant recipients. Transplant Proc 2014, 2:415-417.
12. Momper JD, Ridenour TA, Schonder KS, Shapiro R, Humar A, Venkataramanan R: The impact of conversion from prograf to generic tacrolimus in liver and kidney transplant recipients with stable graft function. Am J Transplant 2011, 11:1861-1867.
13. Christians U, Klawitter J, Clavijo CF: Bioequivalence testing of immunosuppressants: concepts and misconceptions. Kidney Int Suppl 2010, 77:S1-S7.
14. Davit BM, Nwakama PE, Buehler GJ, Conner DP, Haidar SH, Patel DT, Yang Y, Yu LX, Woodcock J: Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration. Ann Pharmacother 2009, 43:1583-1597.
15. Yu Y, Teerenstra S, Vanmolkot F, Neef C, Burger D, Maliepaard M: Interchangeability of gabapentin generic formulations in the Netherlands: a comparative bioavailability study. Clin Pharmacol Ther 2013, 94:519-524.
16. Alloway RR, Isaacs R, Lake K, Hoyer P, First R, Helderman H, Bunnapradist S, Leichtman A, Bennett MW, Tejani A, Takemoto SK: Report of the american society of transplantation conference on immunosuppressive drugs and the Use of generic immunosuppressants. Am J Transplant 2003, 3:1211-1215.
17. Gordon EJ, Prohaska TR, Sehgal AR: The financial impact of immunosuppressant expenses on new kidney transplant recipients. Clin Transplant 2008, 22:738-748.
18. van Gelder T: European Society for Organ Transplantation Advisory Committee recommendations on generic substitution of immunosuppressive drugs. Transpl Int 2011, 24:1135-1141.
19. Le Meur Y, Sebbag L, Anglicheau D, Kama N, Billaud E, Hulin A, Marquet P: Recommandation de la Société francophone de transplantatelon sur l'utilisation des génériques des immunosuppresseurs. Le Courrier de la Transplant 2012, 12:102-106.
20. Roemer JE: Theories of Distributive Justice. Cambridge, Mass: Harvard University Press; 1998.
21. Beauchamp TL, Childress JF: Principles of Biomedical Ethics. New York, NY: Oxford University Press; 2001.
22. Daniels N: Justice, health, and healthcare. Am J Bioeth 2001, 2:2-16.
23. Minogue B: The two fundamental duties of the physician. Acad Med 2000, 75:431-442.
24. Pellegrino ED: The medical profession as a moral community. Bull N Y Acad Med 1990, 3:221-232.
25. Kassirer JP: Our endangered integrity - It Can only Get worse. New Engl J Med 1997, 23:1666-1667.
26. Dyer AR: Patients, not costs, come first: should doctors cut costs at the bedside? Hastings Cent Rep 1986, 16:5-7.
27. Beach MC, Meredith LS, Halpern J, Wells KB, Ford DE: Physician conceptions of responsibility to individual patients and distributive justice in health care. Ann Fam Med 2005, 3:53-59.
28. Strech D, Persad G, Marckmann G, Danis M: Are physicians willing to ration health care? Conflicting findings in a systematic review of survey research. Health Policy 2009, 2-3:113-124.
29. Maynard A: Health care rationing: doing it better in public and private health care systems. J Health Polit Policy Law 2013, 38:1103-1127.
30. Cattaneo D, Perico N, Remuzzi G: Generic cyclosporine formulations: more open questions than answers. Transpl Int 2005, 4:371-378.
31. Min SI, Ha J, Kim YS, Ahn SH, Park T, Park DD, Kim SM, Min SK, Hong H, Ahn C, Kim SJ: Therapeutic equivalence and pharmacokinetics of generic tacrolimus formulation in de novo kidney transplant patients. Nephrol Dial Transplant 2013, 12:3110-3119.
32. Pamugas GE, Danguilan RA, Lamban AB, Mangati VB, Ona ET: Safety and efficacy of generic cyclosporine arpimune in Filipino low-risk primary kidney transplant recipients. Transplant Proc 2012, 1:101-108.
33. Spence MM, Nguyen LM, Hui RL, Chan J: Evaluation of clinical and safety outcomes associated with conversion from brand-name to generic tacrolimus in transplant recipients enrolled in an integrated health care system. Pharmacotherapy 2012, 11:981-987.
34. Devaney A, Lee M: The use of generic immunosuppression for transplant patients: a UK perspective. Eur J Hosp Pharm 2013, 20:272-274.
35. Uber PA, Ross HJ, Zuckermann AO, Sweet SC, Corris PA, McNeil K, Mehra MR: Generic Drug Immunosuppression in Thoracic Transplantation: An ISHLT Educational Advisory. J Heart Lung Transplant 2009, 7:655-660.
36. Blumenthal D: Doctors and Drug Companies. New Engl J Med 2004, 18:1885-1890.
37. Wazana A: Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA 2000, 3:373-380.
38. Lynas K: Private insurers implementing policies making generic substitution mandatory. Can Pharm J Revue des Pharmaciens du Canada 2012, 6:245.
39. The Canadian Generic Pharmaceutical Association: The Canadian Generic Market Year 2012. Montreal: Association TCGP; 2013. [cited 2014 April 23rd]. Available from: http://www.canadiangenerics.ca/fr/resources/market_trends.asp.
40. Sabatini S, Ferguson RM, Helderman JH, Hull AR, Kirkpatrick BS, Barr WH: Drug substitution in transplantation: A National Kidney Foundation white paper. Am J Kidney Dis 1999, 2:389-397.
41. Labrie Y: How can we Prevent Drug Shortage. Montréal: Montreal Economic Institute; 2012.